PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2018

Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.

Rat / Spinal cord injury

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 29931461 ↗2018Reported benefit

Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.

RatSpinal cord injuryComplete transectionWistarMalen = Sham n = 10, spinal cord injury plus vehicle n = 11, spinal…Subcutaneous25 mg/kg per weekStarted 12 weeks after spinal cord transection

Model: Complete spinal cord transection (chronic motor-complete spinal cord injury), with laminectomy-only sham

At 20 weeks after injury, vehicle-treated transected rats had lower bone mineral density at the distal femur, proximal tibia and lumbar spine (about -22, -15 and -9 per cent versus sham), reduced trabecular bone volume (-37.2 per cent) and connectivity (-53.2 per cent), reduced cortical thickness (…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.